Synthesis of bufalin derivatives with inhibitory activity against prostate cancer cells

被引:12
作者
Yuan, Xiao-Feng [1 ]
Tian, Hai-Yan [1 ]
Li, Juan [1 ]
Jin, Lu [1 ,2 ]
Jiang, Shu-Tai [1 ]
Liu, Ken Wing-Keung [3 ]
Luo, Cheng [2 ]
Middleton, David A. [4 ]
Esmann, Mikael [5 ]
Ye, Wen-Cai [1 ]
Jiang, Ren-Wang [1 ]
机构
[1] Jinan Univ, Coll Pharm, Guangdong Prov Key Lab Pharmacodynam Constituents, Guangzhou 510632, Guangdong, Peoples R China
[2] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China
[3] Chinese Univ Hong Kong, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China
[4] Univ Liverpool, Inst Integrat Biol, Liverpool L69 7ZQ, Merseyside, England
[5] Aarhus Univ, Dept Biomed, DK-8000 Aarhus, Denmark
基金
中国国家自然科学基金;
关键词
bufalin; prostate cancer; Na+; K+-ATPase; androgen receptor; ANDROGEN-RECEPTOR-ANTAGONIST; THERAPY;
D O I
10.1080/14786419.2014.881363
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
Bufalin possesses a strong anti-cancer effect, but the cardiac toxicity targeting the Na+, K+-ATPase limits its application. Here, two bufalin derivatives, bufadienolactam (1) and secobufalinamide (2), were synthesised by treating bufalin with ammonium acetate in dimethylformamide solution. Their structures were elucidated by extensive spectroscopic methods. The structure of compound 2 was further confirmed by single-crystal X-ray diffraction analysis. Compounds 1 and 2 expressed strong inhibitory activities against androgen-dependent prostate cancer cells (IC50 values about 10 mu M), but only weak inhibition on Na+, K+-ATPase (K-i about 70 mu M), indicating that they might be potential anti-prostate cancer agents without severe cardiac toxicity.
引用
收藏
页码:843 / 847
页数:5
相关论文
共 11 条
  • [1] International epidemiology of prostate cancer: Geographical distribution and secular trends
    Baade, Peter D.
    Youlden, Danny R.
    Krnjacki, Lauren J.
    [J]. MOLECULAR NUTRITION & FOOD RESEARCH, 2009, 53 (02) : 171 - 184
  • [2] Molecular determinants of resistance to antiandrogen therapy
    Chen, CD
    Welsbie, DS
    Tran, C
    Baek, SH
    Chen, R
    Vessella, R
    Rosenfeld, MG
    Sawyers, CL
    [J]. NATURE MEDICINE, 2004, 10 (01) : 33 - 39
  • [3] Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system
    Culig Z.
    Hoffmann J.
    Erdel M.
    Eder I.E.
    Hobisch A.
    Hittmair A.
    Bartsch G.
    Utermann G.
    Schneider M.R.
    Parczyk K.
    Klocker H.
    [J]. British Journal of Cancer, 1999, 81 (2) : 242 - 251
  • [4] MDV-3100 Androgen Receptor Antagonist Prostate Cancer Therapy
    Gao, L.
    Alumkal, J.
    [J]. DRUGS OF THE FUTURE, 2011, 36 (05) : 371 - 376
  • [5] Androgen receptor outwits prostate cancer drugs
    Isaacs, JT
    Isaacs, WB
    [J]. NATURE MEDICINE, 2004, 10 (01) : 26 - 27
  • [6] A Novel Dietary Flavonoid Fisetin Inhibits Androgen Receptor Signaling and Tumor Growth in Athymic Nude Mice
    Khan, Naghma
    Asim, Mohammad
    Afaq, Farrukh
    Abu Zaid, Mohammad
    Mukhtar, Hasan
    [J]. CANCER RESEARCH, 2008, 68 (20) : 8555 - 8563
  • [7] Kish J A, 2001, Cancer Control, V8, P487
  • [8] Roger JB, 2002, LIFE SCI, V72, P699
  • [9] Lupeol, a Novel Androgen Receptor Inhibitor: Implications in Prostate Cancer Therapy
    Siddique, Hifzur Rahman
    Mishra, Shrawan Kumar
    Karnes, R. Jeffery
    Saleem, Mohammad
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (16) : 5379 - 5391
  • [10] A bufadienolide derived androgen receptor antagonist with inhibitory activities against prostate cancer cells
    Tian, Hai-Yan
    Yuan, Xiao-Feng
    Jin, Lu
    Li, Juan
    Luo, Cheng
    Ye, Wen-Cai
    Jiang, Ren-Wang
    [J]. CHEMICO-BIOLOGICAL INTERACTIONS, 2014, 207 : 16 - 22